Olr421 inhibitors represent a specific class of chemical compounds that target the Olr421 protein, a member of the olfactory receptor (OR) family. Olfactory receptors are G-protein-coupled receptors (GPCRs) primarily known for their role in the detection of odorants in the nasal epithelium, but they are also expressed in various other tissues and cells. The Olr421 protein, encoded by the Olr421 gene, is one such receptor, and its inhibitors are designed to selectively bind to this protein, blocking its activity. This inhibition can occur through various mechanisms, such as direct antagonism at the binding site, allosteric modulation, or by interfering with the receptor's ability to interact with its associated G-proteins. The specificity of these inhibitors is crucial, as it allows for the selective targeting of Olr421 without affecting other olfactory receptors or GPCRs, thereby minimizing off-target effects that could complicate experimental outcomes.
The development of Olr421 inhibitors involves extensive research into the molecular structure of the Olr421 receptor, particularly its ligand-binding domains and the associated signaling pathways. Structural biology techniques such as X-ray crystallography, cryo-electron microscopy, and computational modeling are often employed to elucidate the three-dimensional conformation of Olr421 and to identify potential binding sites for inhibitors. High-throughput screening methods are typically used to identify candidate molecules, which are then optimized for improved binding affinity and selectivity. This optimization process may involve modifications to the chemical structure of the inhibitor to enhance its interaction with the Olr421 receptor, as well as to improve its physicochemical properties such as solubility, stability, and permeability. The study of Olr421 inhibitors is significant for understanding the broader physiological roles of olfactory receptors beyond olfaction, as well as for advancing the fundamental knowledge of GPCR function and regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Azilsartan | 147403-03-0 | sc-503231 sc-503231A sc-503231B sc-503231C sc-503231D sc-503231E | 10 mg 50 mg 100 mg 250 mg 500 mg 1 g | $140.00 $180.00 $230.00 $370.00 $490.00 $781.00 | ||
Angiotensin II receptor blocker, can indirectly modulate GPCR signaling, potentially impacting Olr421. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Angiotensin II receptor antagonist, might affect GPCR signaling indirectly, impacting Olr421. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Calcium channel blocker, could alter GPCR signaling indirectly through calcium ion dynamics, impacting Olr421. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
Mineralocorticoid receptor antagonist, may influence GPCR signaling indirectly, affecting Olr421. | ||||||
Irbesartan | 138402-11-6 | sc-218603 sc-218603A | 10 mg 50 mg | $106.00 $303.00 | 3 | |
Angiotensin II receptor antagonist, can modulate GPCR signaling pathways indirectly, impacting Olr421. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor blocker, might indirectly affect GPCR signaling, impacting Olr421. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Beta-1 adrenergic receptor blocker, could influence GPCR signaling indirectly, impacting Olr421. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
Angiotensin II receptor blocker, can indirectly affect GPCR signaling, potentially impacting Olr421. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Angiotensin II receptor antagonist, might alter GPCR signaling indirectly, impacting Olr421. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, could influence GPCR signaling indirectly through calcium modulation, impacting Olr421. | ||||||